Cullinan Therapeutics will host an analyst and investor webcast on Sept. 14 to discuss Phase 3 REZILIENT3 results for zipalertinib, marking a key catalyst for the biotech. The data on zipalertinib plus chemotherapy will debut first at the IASLC 2026 lung cancer meeting.
published
Cullinan Therapeutics will host an analyst and investor webcast on Sept. 14 to discuss Phase 3 REZILIENT3 results for zipalertinib, marking a key catalyst for the biotech. The data on zipalertinib plus chemotherapy will debut first at the IASLC 2026 lung cance
Latest documented BWB result
$META market result
I sold the $META $655 Puts 9/25 for $7.60
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.